Skip to main content

Sessions

Preliminary programme

5th Central European Biomedical Congress, Kraków, Poland,
May 29 – June 1, 2023, Future trends in health interventions
Venue: Auditorium Maximum, 33 Krupnicza Street, Krakow, Poland

Monday, May 29, 2023
8.00 a.m. – 5.00 p.m. Registration
9.30 – 10.30 a.m. – Large Hall Plenary lecture
Professor Gustavo Turecki PhD, MD
Douglas Hospital Research Centre, McGill Group for Suicide Studies, Montreal, Quebec, Canada
Chair persons: Professor Marta Dziedzicka-Wasylewska, PhD; Agata Faron Górecka, PhD
TBA
10.30 – 11.00 a.m. – Exhibition Room Coffee break
11.00 – 12.30 p.m. – Medium Hall A Session 1: Blood-brain barrier dysfunction in CNS disorders
Chair persons: Professor Marta Dziedzicka-Wasylewska, PhD, Agata Faron Górecka, PhD
S. 01-1
Professor Marta Dziedzicka-Wasylewska, PhD
Maj Institute of Pharmacology, Polish Academy of Sciences, Kraków, Poland
Potential role of blood-brain barrier in stress resilience
S. 01-2
Agnieszka Chocyk, PhD
Maj Institute of Pharmacology, Polish Academy of Sciences, Kraków, Poland
Sex-specific effects of early-life stress on blood-brain barrier function and response to immune challenge in rats
S. 01-3
Barbara Błasiak, PhD
Institute of Nuclear Physics Polish Academy of Sciences, Kraków, Poland
MRI Contrast Agents Crossing Blood-Brain Barrier
11.00 – 12.30 p.m. – Medium Hall B Session 2: Mass spectrometry in medical sciences
Chair person: Przemysław Mielczarek, PhD
S. 02-1
Professor Giuseppe Grasso, PhD
University of Catania, Catania, Italy
TBA
S. 02-2
Professor Vladimir Havlicek, PhD
Institute of Microbiology of the Czech Academy of Sciences, Prague, Czech Republic
Next generation infection diagnostics
S. 02-3
Professor Anna Bodzon-Kulakowska, PhD
AGH University of Science and Technology, Krakow, Poland
TBA
S. 02-4
Joanna Kasprzyk-Pochopień, M.Sc
JagiellonianUniversity, Krakow, Poland
TBA
12.30 – 1.00 p.m. – Medium Hall A, B Sponsor presentation
1.00 – 2.30 p.m. – Medium Hall A Session 3: Theranostic nanocarriers for drug delivery in central nervous system disorders
Chair persons: Professor Władysław Lasoń, PhD; Professor Piotr Warszyński, PhD
S. 03-1
Juan Yang, PhD
Functional Ceramics and Nanomaterials, SINTEF, Oslo, Norway
Progress of Engineered nanoparticls as theranostic nanocarriers
S. 03-2
Krzysztof Szczepanowicz , PhD
Jerzy Haber Institute of Catalysis and Surface Chemistry, Polish Academy of Sciences, Krakow, Poland
Synthesis and characterization of polymer-based theranostic nanoparticles containing carnosic acid
S. 03-3
Danuta Jantas, PhD
Maj Institute of Pharmacology, Polish Academy of Sciences, Kraków, Poland
Biosafety and neuroprotective potency of polymer-based theranostic nanoparticles containing carnosic acid
S. 03-4
Rugmani Meenambal, PhD
Maj Institute of Pharmacology, Polish Academy of Sciences, Kraków, Poland
Polyacrylic acid (PAA) conjugated cerium oxide nanoparticles as efficient neuroprotectants against oxidative stress-induced cell damage in human neuronal-like cells
1.00 – 2.30 p.m. – Medium Hall B Session 4: Modern approaches in immunodiagnostics and immunotherapy
Chair person: Professor Maciej Siedlar, PhD
TBA
S. 04-1
Professor Maciej Siedlar, PhD
Institute of Paediatrics, Jagiellonian University Medical College, Kraków, Poland
TBA
S. 04-2
Proffessor Marcin Majka, PhD
Institute of Paediatrics, Jagiellonian University Medical College, Kraków, Poland
Future of cell-based therapeutics in the light of today’s developments.
S. 04-3
Professor Gabriela Kania, PhD
University of Zurich, Center of Experimental Theumatology, Zurich, Switzerland
Tale of two tubes exploring pathological mechanisms in systemic sclerosis – focus on monocytes and macrophages
2.30 – 3.00 p.m. – Exhibition Room Coffee break
3.00 – 3.15 p.m. – Large Hall Welcome ceremony
Chair persons: Honorary Committee & Organizing Committee
3.15 – 4.15 p.m. Inaugural lecture
Professor Véronique Deroche-Gamonet PhD, HDR
Université de Bordeaux, INSERM, Neurocentre Magendie, Bordeaux, France
Chair person: Jan Rodriguez-Parkitna, PhD
TBA
4.15 – 4.30 p.m. Promotion of the city of Krakow and the Maj Institute of Pharmacology Polish Academy of Sciences – Large hall
4.30 – 5.30 p.m. – Large Hall Music performance
5.30 – 9.00 p.m. – Exhibition Room Welcome party
Tuesday, 30 May 2023
9.00 – 10.30 a.m. – Medium Hall A Session 5: The burden of neurodegenerative and psychiatric disorders: trends and future treatment
Chair person: Professor Katarzyna Starowicz – Bubak, PhD
S. 05-1
Professor Aron H. Lichtman, PhD
Virginia Commonwealth University, Richmond, VA, USA
TBA
S. 05-2
Professor Danilo De Gregorio, PhD
Vita-Salute University and San Raffaele Scientific Institute, Milan, Italy
Therapeutic use of psychedelics in mental health
S. 05-3
Iskra Pollak Dorocic
Stockholm University, Stockholm, Sweeden
Transcriptional effects of SSRI administration on brain networks
9.00 – 10.30 a.m. – Medium Hall B Session 6: Sphingolipids in health and brain diseases
Chair persons: Professor Christian P. Muller, PhD; Małgorzata Frankowska, PhD
S. 06-1
Professor Christian P. Muller, PhD
Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany
Sphingolipids in the brain: from memory control to psychiatric disorders 
S. 06-2
Alessandro Prinetti, PhD
University of Milano, Italy
Sphingolipids orchestrating the cross-talk between different cell populations in the formation of myelin and in the repair of damaged myelin
S. 06-3
Vittorio Maglione, PhD
Neuromed, Pozzilli, Italy
Sphingolipid alterations in Huntington’s disease: new insights into molecular mechanisms and potential therapies
10.30 – 11.00 a.m. – Medium Hall A, B Sponsor presentation
11.00 – 11.30 a.m. – Exhibition Room Coffee break
11.30 – 12.30 p.m. – Medium Hall Plenary lecture
Professor Johannes Kornhuber, PhD, MD
Friedrich-Alexander-Universität Erlangen-Nürnberg University Hospital, Erlangen, Germany
Chair person: Professor Małgorzata Filip, PhD, Professor Joanna Pera, PhD
TBA
12.30 – 1.30 p.m. – Exhibition Room Poster session 1
Lunch break
1.30 – 3.00 p.m. – Medium Hall A Session 7: Digital medicine – beyond diagnostics
Chair person: Klaudia Proniewska, PhD
S. 07-1
Klaudia Proniewska, PhD
Jagiellonian University Medical College, Krakow, Poland
TBA
S. 07-2
Danila Potyagaylo
EPIQure GmbH, Nuremberg, Germany
Combination of 12-lead ECG with patient-specific anatomical data for personalized cardiology and electrophysiology 
S. 07-3
Peter van Dam
TBA
TBA
1.30 – 3.00 p.m. – Medium Hall B Session 8: New targets, new ligands, new drugs: a novel approach for the treatment of the CNS pathologies
Chair persons: Professor Małgorzata Kajta, PhD; Agnieszka Wnuk, PhD
S. 08-1
Adib Zendedel, PhD
Institute of Neuroanatomy, Medical Faculty, RWTH Aachen University, Aachen, Germany
The role of microglial-derived extracellular vesicles in the pathogenesis of traumatic spinal cord injury: implication of exosomal microRNAs
S. 08-2
Professor Joanna Śliwowska, PhD
Poznań University of Life Sciences, Poznań, Poland
Metabolic and reproductive dysfunctions associated with obesity and diabetes: From the womb to adulthood
S. 08-3
Agnieszka Wnuk, PhD
Maj Institute of Pharmacology, Polish Academy of Sciences, Krakow, Poland
Emerging evidence for triclocarban as a neurodevelopmental risk factor: disruption of epigenetic status and dysregulation of neurogenesis-related genes.
S. 08-4
Professor Małgorzata Kajta, PhD
Maj Institute of Pharmacology, Polish Academy of Sciences, Krakow, Poland
New treatment strategies against neural degenerations based on selective targeting of membrane estrogen receptors and PPARγ 
3.00 – 3.30 p.m. – Exhibition Room Coffee break
3.30 – 5.00 p.m. – Medium Hall A Session 9: Chaperons in Gaucher’s disease
Chair person: Professor Beata Kieć-Wilk, PhD
S. 09-1
TBA
TBA
TBA
S. 09-2
TBA
TBA
TBA
S. 09-3
TBA
TBA
TBA
3.30 – 5.00 p.m. – Medium Hall B Session 10: Tracking brain projections and cell signaling involved in neuroadaptations triggered by cocaine, stress, or neurodegeneration
Chair persons: Grzegorz Kreiner, PhD; Agnieszka Zelek-Molik, PhD
S. 10-1
Rachel J. Smith, PhD
Texas A&M University, USA
Investigating the link between habitual cocaine seeking and punishment resistance in rat models of addiction
S. 10-2
Yonatan Kupchik
The Institute for Medical Research Israel-Canada (IMRIC), The Hebrew University of Jerusalem, Israel
Multimodal differences between projections of the ventral pallidum and relevance to cocaine reward 
S. 10-3
Agnieszka Zelek-Molik, PhD
Maj Institute of Pharmacology, Polish Academy of Sciences, Kraków
Psychosocial crowding stress affects neuroplasticity-related signalling pathways within rats’ frontal cortex in a region-dependent manner 
S.10-4
Justyna Barut, MSc
Maj Institute of Pharmacology, Polish Academy of Sciences, Kraków
Utilization of conditional single lentivirus CRISPR/Cas9 vector for efficient gene knockout generation in adult neurons in vivo and in vitro as potential new model for study prodromal phase of Parkinson’s disease 
Wednesday, 31 May 2023
9.00 – 10.30 a.m. – Medium Hall A Session 11: Medical biotechnology in disease modelling, drug research and therapy
Chair person: Professor Józef Dulak, PhD
S. 11-1
Professor Józef Dulak, PhD; Professor Agnieszka Łoboda, PhD
Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Krakow, Poland
Stem cells in neurological diseases modelling and therapies: possibilities, hopes and hypes.
S. 11-2
Florence Rage, PhD
Institute de Genetique Moleculaire, CNRS, Montpellier, France
Human NMJ: from a single chip to a Simplified Miniature Array (SMA) for drugs screening
S. 11-3
Sifeng Chen, PhD
Department of Physiology and Pathophysiology, School of Basic Medical Sciences, Fudan University, Shanghai, People’s Republic of China
The therapeutic effects of induced pluripotent stem cells and their exosomes on cardiovascular diseases
9.00 – 10.30 a.m. – Medium Hall B Session 12: Novel rapid-acting antidepressants
Chair persons: Bernadeta Szewczyk, PhD; Professor Andrzej Pilc, PhD
S. 12-1
Professor Jeffrey M Witkin, PhD
University of Wisconsin – Milwaukee, USA
New age antidepressants create new ways to think about treatment
S. 12-2
Professor Laura Musazzi, PhD
School of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy
Molecular signature of ketamine – response/non-response in a preclinical model of depression
S. 12-3
Professor Shigeyuki Chaki, PhD
Taisho Pharmaceutical, Japan
Ketamine-like antidepressant potential of mGlu2/3 receptor antagonists
and progress of other candidates targeting the glutamatergic system
10.30 – 11.00 a.m. – Medium Hall A, B Sponsor presentation
11.00 – 11.30 a.m. – Exhibition Room Coffee break
11.30 – 12.30 p.m. – Medium Hall Plenary lecture
Professsor Stefan Chłopicki, PhD, MD
Jagiellonian Centre for Experimental Therapeutics (JCET), Jagiellonian University, Krakow, Poland
Chair person: Professor Małgorzata Filip, PhD
TBA
12.30 – 1.30 p.m. – Exhibition Room Poster session 2
Lunch break
1.30 – 3.00 p.m. – Medium Hall A Session 13: Innovative nanocarriers and treatment modalities in antitumor therapy
Chair person: Professor Bożena Kaczmarek, PhD
S. 13-1
Professor Bożena Kamińska-Kaczmarek, PhD
Nencki Institute of Experimental Biology of the Polish Academy of Sciences, Warsaw, Poland
Reinvigorating antitumor immunity in brain tumors with short peptides and siRNA-nanocarriers targeting the tumor microenvironment
S. 13-2
Professor Ling Peng, PhD
Aix-Marseille University, Marseille, France
Modular and adaptive dendrimer nanosystems in cancer treatment
S. 13-3
Professor Tambet Tessalu, PhD
University of Tartu, Tartu, Estonia
Targeting of nanoparticles with homing peptides
1.30 – 3.00 p.m. – Medium Hall B Session 14: Duchenne muscular dystrophy and its complications – new tools and mechanisms for possible treatments
Chair persons: Professor Agnieszka Łoboda, PhD
S. 14-1
Maurilio Sampaolesi
KU Leuven, Leuven, Belgium
Harnessing novel 3D stem cell-based models to challenge dystrophic cardiomyopathy
S. 14-2
Jacek Stępniewski
Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Kraków, Poland
Human induced pluripotent stem cells and gene editing for modelling of Duchenne muscular dystrophy-associated cardiomyopathy
S. 14-3
Professor Agnieszka Łoboda, PhD
Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Krakow, Poland
Hydrogen sulfide donors: therapeutic potential in Duchenne muscular dystrophy
3.00 – 3.30 p.m. – Exhibition Room Coffee break
3.30 – 5.00 p.m. – Medium Hall A Session 15: Future therapies with psychodelics
Chair person: Professor Krystyna Gołembiowska, PhD
S. 15-1
Professor Charles Nichols, PhD
LSU Health Sciences Center, New Orleans, LA, US
A single treatment with psychedelics can produce persistent antidepressant-like effects, and changes in functional plasticity across several types of depression models in both rats and fruit flies
S. 15-2
Urszula Kozłowska
Institute of Bioorganic Chemistry, Polish Academy of Sciences, Poznań, Poland
Psychedelics immunomodulatory effect on microglia and its prospect meaning for neurodegenerative diseases treatment.
5.00 – 6.00 p.m. – Seminar Room, Conference Room Workshop
CEPHARES – a new R&D division of Maj Institute of Pharmacology. Mission, opportunities, perspectives
TBA
8.00 – 11.00 p.m. Congress dinner – Kościuszko Mound in Kraków, 1 Washington Avenue
Thursday, 1 June 2023
9.00 – 10.00 a.m. – Large Hall Plenary lecture
Professor Kathryn A. Cunningham, PhD
The University of Texas Medical Branch at Galveston, USA
Chair person: Professor Małgorzata Filip, PhD
TBA
10.00 – 10.30 a.m. – Exhibition Room Coffee break
10.30 – 12.00 a.m. – Large Hall Session 16: Magnificent Seven: on the role of the 5-HT7R receptor in the brain
Chair person: Monika Bijata, PhD, Professor Paweł Zajdel, PhD
S. 16-1
Morisset-Lopez
Molecular Biophysics Center, The University of Orléans, INSERM, France
Discovery of biased ligands of 5-HT7R to illuminate the receptor biology
S. 16-2
Professor Evgeni Ponimaskin, PhD
Hannover Medical School, Hannover, Germany
Targeting the serotonin receptor 7 (5-HT7R) ameliorates Tau pathology and memory deficits
S. 16-3
Jakub Włodarczyk, PhD
Nencki Institute of Experimental Biology of Polish Academy of Science, Warsaw, Poland
The molecular fingerprint of stress resilience
12.00 -12.30 p.m. Lunch break – Exhibition Room
12.30 a.m. – 1.30 p.m. – Medium Hall Plenary lecture
Professor Stéphane Oliet, PhD
Bordeaux Neurocampus, University de Bordeaux, France
Chair person: Professor Joanna Pera, MD, PhD
TBA
1.30 – 2.45 p.m. Session 17:
Young scientific investigators’ session
75 min, Medium Hall
Chair person: Professor Rafał Ryguła, PhD
2.45 – 3.15 p.m. Closing & Award ceremony – Medium Hall
Chair persons: Professor Małgorzata Filip, PhD, Professor Joanna Pera, PhD